Other equities analysts also recently issued research reports about the stock. Zacks Investment Research downgraded shares of Kamada from a strong-buy rating to a hold rating in a research note on Wednesday, July 24th. Chardan Capital reiterated a buy rating and issued a $7.00 target price on shares of Kamada in a research note on Friday, May 17th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company’s stock. Kamada currently has an average rating of Hold and an average target price of $8.17.
Shares of KMDA stock remained flat at $$5.55 on Thursday. 308 shares of the stock traded hands, compared to its average volume of 29,480. The company has a 50-day moving average of $5.67. The company has a market capitalization of $226.66 million, a P/E ratio of 10.09 and a beta of 1.17. The company has a current ratio of 5.29, a quick ratio of 3.82 and a debt-to-equity ratio of 0.04. Kamada has a 52 week low of $4.63 and a 52 week high of $6.70.
Several institutional investors and hedge funds have recently made changes to their positions in the company. Nkcfo LLC bought a new stake in shares of Kamada in the 1st quarter worth approximately $26,000. Meitav Dash Investments Ltd. increased its stake in shares of Kamada by 3.1% in the first quarter. Meitav Dash Investments Ltd. now owns 909,912 shares of the biotechnology company’s stock worth $5,201,000 after buying an additional 27,405 shares during the period. Norges Bank purchased a new position in shares of Kamada in the fourth quarter worth $219,000. Marshall Wace LLP purchased a new position in Kamada during the 1st quarter valued at $276,000. Finally, Acadian Asset Management LLC increased its position in Kamada by 41.8% during the 1st quarter. Acadian Asset Management LLC now owns 945,878 shares of the biotechnology company’s stock valued at $5,422,000 after purchasing an additional 278,674 shares during the period. Hedge funds and other institutional investors own 12.89% of the company’s stock.
Kamada Ltd. develops, produces, and markets plasma-derived protein therapeutics for orphan indications. It operates through two segments, Proprietary Products and Distribution. The company offers respiratory products, including Glassia for use in augmentation and maintenance therapy in adults with emphysema due to congenital Alpha-1 Antitrypsin (AAT) deficiency.
Read More: Quiet Period
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Kamada Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kamada and related companies with MarketBeat.com's FREE daily email newsletter.